Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Long

Showing results (261-270 of 703) with videos related to

Pageof 71
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2015
PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma PatientsHojabr Kakavand, James S Wilmott, Alexander M Menzies, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2024
Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapyAljosja Rogiers, Florentia Dimitriou, Irene Lobon, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 5, 2017
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patientsHojabr Kakavand, Louise A Jackett, Alexander M Menzies, et al.
Molecular and Cellular Biochemistry|September 16, 2017
Multiple non-catalytic ADAMs are novel integrin α4 ligandsLei Wang, Jason A Hoggard, Erica D Korleski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2017
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced MelanomaJeffrey S Weber, F Stephen Hodi, Jedd D Wolchok, et al.
Investigational New Drugs|May 31, 2022
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 studyStergios J Moschos, Shahneen Sandhu, Karl D Lewis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2025
Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic TumorsIsmael A Vergara, Nigel G Maher, Alison J Potter, et al.
Australian Family Physician|August 11, 2016
Sentinel node biopsy for melanoma: The medical oncology perspectiveAlexander M Menzies, Victoria G Atkinson, Michael P Brown, et al.
ESMO Open|November 7, 2025
Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failureI P da Silva, L Zimmer, J-Y Blay, et al.
JAMA Network Open|February 17, 2026
Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical TrialSancy A Leachman, Jason J Luke, Paolo A Ascierto, et al.
Pageof 71

Showing results (261-270 of 703) with videos related to

Sort By:
Pageof 71
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2015
PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma PatientsHojabr Kakavand, James S Wilmott, Alexander M Menzies, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2024
Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapyAljosja Rogiers, Florentia Dimitriou, Irene Lobon, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 5, 2017
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patientsHojabr Kakavand, Louise A Jackett, Alexander M Menzies, et al.
Molecular and Cellular Biochemistry|September 16, 2017
Multiple non-catalytic ADAMs are novel integrin α4 ligandsLei Wang, Jason A Hoggard, Erica D Korleski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2017
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced MelanomaJeffrey S Weber, F Stephen Hodi, Jedd D Wolchok, et al.
Investigational New Drugs|May 31, 2022
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 studyStergios J Moschos, Shahneen Sandhu, Karl D Lewis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2025
Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic TumorsIsmael A Vergara, Nigel G Maher, Alison J Potter, et al.
Australian Family Physician|August 11, 2016
Sentinel node biopsy for melanoma: The medical oncology perspectiveAlexander M Menzies, Victoria G Atkinson, Michael P Brown, et al.
ESMO Open|November 7, 2025
Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failureI P da Silva, L Zimmer, J-Y Blay, et al.
JAMA Network Open|February 17, 2026
Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical TrialSancy A Leachman, Jason J Luke, Paolo A Ascierto, et al.
Pageof 71